INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5388 participants.

Also called NCT02787044

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 5,388 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02787044
Main results
  • Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial JAMA, 2021-01-05 DOI, PubMed 33275134, PMC7718608 Not in the PMC Open Access subset.
Other papers using this trial's data
  • Educational Attainment Level and Risk of Mortality and Cardiopulmonary Outcomes in High-Risk Patients With Cardiovascular Disease: The INVESTED Trial Journal of the American Heart Association, 2025-07 DOI, PubMed 40530474, PMC12449914 In the PMC Open Access subset under CC BY-NC-ND.
  • Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical Trial JAMA cardiology, 2024-06-01 DOI, PubMed 38583091, PMC11000133 In the PMC Open Access subset under CC BY.
  • Temporal Association Among Influenza-Like Illness, Cardiovascular Events, and Vaccine Dose in Patients With High-Risk Cardiovascular Disease: Secondary Analysis of a Randomized Clinical Trial JAMA network open, 2023-09-05 DOI, PubMed 37707817, PMC10502520 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02787044. Randomized; quadruple masking; primary purpose prevention. Start 2016-08-01 (actual); primary completion 2020-05-31 (actual). Results posted on 2021-09-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
Acronym
INVESTED
Condition
Heart Failure
Intervention (Biological)
High Dose Trivalent Influenza Vaccine
Intervention (Biological)
Standard Dose Quadrivalent Influenza Vaccine
Lead sponsor
Brigham and Women's Hospital (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)
Collaborator
University of Wisconsin, Madison (class: other)
Collaborator
University of Toronto (class: other)
Collaborator
Boston VA Research Institute, Inc. (class: other)
Collaborator
Patient-Centered Outcomes Research Institute (class: other)
Collaborator
University of Minnesota (class: other)

Record details

Record id
cardio:ct-nct02787044
Content hash
658c467b38955800a4142f1b08c508b0b855be2f5482dad81dc5a931b2254478